Le Lézard
Classified in: Health
Subjects: LAW, OBI, CFG

Death of an inmate from Bowden Institution


INNISFAIL, AB, May 4, 2022 /CNW/ - On May 2, 2022, Kenneth Savage, an inmate from Bowden Institution, died while in our custody of apparent natural causes.

At the time of death, the inmate had been serving an indeterminate sentence, which commenced on March 9, 1967, as a dangerous sexual offender.

The inmate's next of kin have been notified.

As in all cases involving the death of an inmate, the Correctional Service of Canada (CSC) will review the circumstances. CSC policy requires that the police and the coroner be notified.

Associated links

CSC Website
Commissioner's Directive: Death of an Inmate
Deaths in custody
Bowden Institution

SOURCE Correctional Services of Canada Prairie Region


These press releases may also interest you

at 20:14
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...

at 19:30
The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against agilon health, inc. ("agilon" or the "Company").  This action, captioned Hope v. agilon health, inc., et...

at 18:00
bioLytical Laboratories Inc. announced today the immediate availability of its INSTI® HCV Antibody Test in the Australian market.  The INSTI Hepatitis C (HCV) Antibody Test is now included in the Australian Register of Therapeutic Goods (ARTG...

at 17:20
The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or...

at 14:15
Endeavor BioMedicines, a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, announced results from a completed Phase 2a clinical trial...

at 12:20
Savara Inc. (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the American Thoracic Society (ATS) 2024 International Conference that is taking place May 17-22, 2024, in San Diego,...



News published on and distributed by: